MINI-FUTURE LONG - ELI LILLY & CO | Real-time Bid/Ask 06:53:23 27/06/2024 pm IST | ||
| 3.05 CHF / 3.07 CHF | 0.00% |
|
| Current month | +31.33% | ||
| 1 month | +32.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 3.06 | -1.29% |
| 25/24/25 | 3.1 | +4.03% |
| 24/24/24 | 2.98 | +2.76% |
| 21/24/21 | 2.9 | -3.33% |
| 20/24/20 | 3 | +2.39% |
Delayed Quote Swiss Exchange
Last update June 26, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYFJU | |
| ISIN | CH1307452651 |
| Date issued | 01/12/2023 |
| Strike | 565.3 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.45 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.1 CHF |
|---|---|
| Lowest since issue | 0.26 CHF |
| Spread | 0.02 CHF |
| Spread % | 0.65% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- LLYFJU Certificat
